Based on the Telix Pharmaceuticals Limited stock forecast from 1 analysts, the average analyst target price for Telix Pharmaceuticals Limited is USD 22.00 over the next 12 months. Telix Pharmaceuticals Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Telix Pharmaceuticals Limited is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Telix Pharmaceuticals Limited’s stock price was USD 16.25. Telix Pharmaceuticals Limited’s stock price has changed by -4.69% over the past week, -3.39% over the past month and 0% over the last year.
No recent analyst target price found for Telix Pharmaceuticals Limited
No recent average analyst rating found for Telix Pharmaceuticals Limited
Company Overview Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. Read Less
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The comp...Read More
Frequently Asked Questions About Telix Pharmaceuticals Limited (TLX) Stock
Based on ratings from 1 analysts Telix Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on TLX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for TLX is USD 22.00 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 22.
TLX stock's Price/Earning ratio is 173.44.
Our analysis grades TLX stock's Price / Earning ratio at F. This means that TLX stock's Price/Earning ratio is above 94% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TLX may be a overvalued for its sector.
The last closing price of TLX's stock was USD 16.25.
The most recent market capitalization for TLX is USD 5.23B.
Based on targets from 1 analysts, the average taret price for TLX is projected at USD 22.00 over the next 12 months.
This means that TLX's stock price may go up by +35.38% over the next 12 months.
We can't find any ETFs which contains Telix Pharmaceuticals Limited's stock.
As per our most recent records Telix Pharmaceuticals Limited has 0 Employees.
Telix Pharmaceuticals Limited's registered address is 55 Flemington Road, North Melbourne, VIC, Australia, 3051.
You can get more information about it from Telix Pharmaceuticals Limited's website at https://telixpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Telix Pharmaceuticals Limited (TLX) Stock
Based on ratings from 1 analysts Telix Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on TLX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for TLX is USD 22.00 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 22.
TLX stock's Price/Earning ratio is 173.44.
Our analysis grades TLX stock's Price / Earning ratio at F. This means that TLX stock's Price/Earning ratio is above 94% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TLX may be a overvalued for its sector.
The last closing price of TLX's stock was USD 16.25.
The most recent market capitalization for TLX is USD 5.23B.
Based on targets from 1 analysts, the average taret price for TLX is projected at USD 22.00 over the next 12 months.
This means that TLX's stock price may go up by +35.38% over the next 12 months.
We can't find any ETFs which contains Telix Pharmaceuticals Limited's stock.
As per our most recent records Telix Pharmaceuticals Limited has 0 Employees.
Telix Pharmaceuticals Limited's registered address is 55 Flemington Road, North Melbourne, VIC, Australia, 3051.
You can get more information about it from Telix Pharmaceuticals Limited's website at https://telixpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TLX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
